about
Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.Drug repurposing and human parasitic protozoan diseasesMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisEffect of alkylphospholipids on Candida albicans biofilm formation and maturationMetabolic signatures of triatomine vectors of Trypanosoma cruzi unveiled by metabolomicsIdentification of unusual phospholipid fatty acyl compositions of Acanthamoeba castellaniiA pathway for phosphatidylcholine biosynthesis in Plasmodium falciparum involving phosphoethanolamine methylationMiltefosine increases lipid and protein dynamics in Leishmania amazonensis membranes at concentrations similar to those needed for cytotoxicity activity.Pharmacotherapeutic options for visceral leishmaniasis-current scenario.Fluorescent labeling of Acanthamoeba assessed in situ from corneal sectioned microscopy.Characterization of Leishmania major phosphatidylethanolamine methyltransferases LmjPEM1 and LmjPEM2 and their inhibition by choline analogsTherapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.Evaluation of leishmanicidal activity and cytotoxicity of Ricinus communis and Azadirachta indica extracts from western Kenya: in vitro and in vivo assays.Miltefosine: oral treatment of leishmaniasis.Adaptations in the lipid metabolism of the protozoan parasite Trypanosoma brucei.Mechanisms of action of lysophospholipid analogues against trypanosomatid parasites.Possible mechanism of miltefosine-mediated death of Leishmania donovani.Synthesis and antifungal activities of miltefosine analogs.Leishmania dihydroxyacetonephosphate acyltransferase LmDAT is important for ether lipid biosynthesis but not for the integrity of detergent resistant membranes.Antimicrobial activity of euplotin C, the sesquiterpene taxonomic marker from the marine ciliate Euplotes crassusDrug delivery systems in the treatment of African trypanosomiasis infections.Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.Antileishmanial structure-activity relationships of synthetic phospholipids: in vitro and in vivo activities of selected derivatives.Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba.Amiodarone destabilizes intracellular Ca2+ homeostasis and biosynthesis of sterols in Leishmania mexicana.The role of Src kinase in the biology and pathogenesis of Acanthamoeba castellanii.Phospholipases a in trypanosomatids.Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation.Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major.A new approach for potential drug target discovery through in silico metabolic pathway analysis using Trypanosoma cruzi genome information.The initial step of glycerolipid metabolism in Leishmania major promastigotes involves a single glycerol-3-phosphate acyltransferase enzyme important for the synthesis of triacylglycerol but not essential for virulence.Leishmania major expresses a single dihydroxyacetone phosphate acyltransferase localized in the glycosome, important for rapid growth and survival at high cell density and essential for virulence.Leishmaniasis in humans: drug or vaccine therapy?
P2860
Q24538756-38BCCA0C-00B8-4169-B591-1BEEBFA15B1FQ26999453-F1673BCF-DE3A-4777-9505-33955D437544Q28271849-02133A14-CFDB-4B4C-A9B4-94F600399D87Q28275463-92A5BB1A-83A8-413A-90CE-D0D98EDFDB5EQ28534750-72D9F904-BA01-49D5-9BA3-8D08F6DBF244Q28540548-0AC854E9-BDF4-4F78-A887-B28D74287B2CQ30046703-90CF1382-8E9B-4AF3-872F-B5EFC38427E4Q33797931-E7EE0539-2346-4E32-BCC3-D64991AD46C3Q34342651-CFB152E6-6D64-40D5-B0BB-DFB7B4DF6C57Q34452377-47327570-E67A-40CA-AC5C-AB1501D1F0BFQ34616125-7424EBAC-BA1C-4FAF-8E8A-A6B6FE72249CQ35606296-F744646C-D532-475C-AD3E-8670F985AA31Q35833805-1DB7EF8F-E744-4CC8-B39B-7F3D11D18EDBQ36441483-4D83D86F-2722-45BF-B399-B15A3285F524Q36571468-6C51456C-C46F-4EFE-8CC5-DA2E7D9752EAQ36576096-AD529E42-E6B3-46AD-8F00-7D933E1822AFQ36669276-05CF887C-491D-4FF9-8528-B204C7662045Q37139795-5E4B5575-B8BF-487C-855B-70E0B3A26582Q37393018-57A8E4B8-4EAF-4B46-8D37-F7AE4439B151Q37568928-165838DB-1E08-472C-83D1-D37121EC514FQ37876880-5773B859-78EB-44DF-BFB6-86D75350EB3BQ39078243-F0345EAC-1D14-424F-A087-2E752AE5E623Q39444305-51DEEAA0-0EC8-4467-AA7C-1AF7AECC204BQ40174125-2C49D43E-B010-454D-93D5-C5A262F4874EQ41041176-5DA991E7-4B1F-41A5-A9B3-F33B9C0924F5Q42133360-FF4A0D29-C7BF-402D-B5F1-3DA5BBACF681Q42159562-3D3163DD-DB05-4BA0-B463-E71CA590AA0CQ42716413-26D847BD-1AAC-444A-B129-5962DA06865CQ43584181-8FDE0C44-59B4-400F-BB06-9CE2B9A7CD1AQ44565936-74389C93-741C-43D5-B9EE-96FC96109667Q45213048-D082E317-D3E9-430B-9D0D-1BECD4E75E01Q46429002-B3EA8B17-22E1-4DCA-BD5C-A03DC0755DBAQ46901900-8C80056B-B772-4D2B-81B7-451AE146967DQ47556262-3A38631F-1BDF-4142-A649-FA0EBDCB32BF
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Antiprotozoal activities of phospholipid analogues.
@ast
Antiprotozoal activities of phospholipid analogues.
@en
type
label
Antiprotozoal activities of phospholipid analogues.
@ast
Antiprotozoal activities of phospholipid analogues.
@en
prefLabel
Antiprotozoal activities of phospholipid analogues.
@ast
Antiprotozoal activities of phospholipid analogues.
@en
P2093
P1476
Antiprotozoal activities of phospholipid analogues.
@en
P2093
Karin Seifert
Michael Duchêne
Simon L Croft
P304
P356
10.1016/S0166-6851(02)00283-9
P577
2003-02-01T00:00:00Z